Plethora and Paul Capital Healthcare sign a $25 million revenue interest financing agreement with an option for an additional $3 million equity ... (eiler Tel: 1 206 713...)

HOME >> BIOLOGY >> TECHNOLOGY

Plethora and Paul Capital Healthcare sign a $25 million revenue interest financing agreement with an option for an additional $3 million equity investment

Date:4/1/2008

eiler Tel: 1 206 713 0124

Email: sseiler@lazarpartners.com

About Paul Capital Partners and Paul Capital Healthcare

Through its multiple funds, Paul Capital Healthcare is one of the largest dedicated healthcare investors globally, with $1.8 billion in equity capital commitments and debt facilities under management. Combined, the Paul Capital Healthcare funds have invested more than $900 million in the pharmaceutical, biotechnology, and medical device sectors. These investments are focused on commercial stage companies and products, and consist of investments in the form of royalties, revenue interests, debt and equity. Additional information on Paul Capital Healthcare can be found at http://www.paulcapitalhealthcare.com. Paul Capital Partners manages nearly $5 billion in equity capital commitments for its three investment platforms, which include Paul Capital Healthcare, Private Equity Secondaries and Top Tier Fund-of-Funds. The firm has offices in New York, San Francisco, Paris, London and Toronto.

About Plethora:

Plethora is focused on the development and marketing of products for the treatment of urological disorders. The Company has products in clinical development for the treatment of overactive bladder, stress urinary incontinence, interstitial cystitis, gynaecological pain, erectile dysfunction and premature ejaculation. In January 2006, Plethora acquired Minneapolis- based Timm Medical Technologies, Inc., which markets products for the treatment of erectile dysfunction (ED) to urology clinics through a US-based specialty sales team. The Company is headquartered in the UK and is listed on the London Stock Exchange (AIM: PLE) Further information is available at http://www.plethorasolutions.co.uk. <
'/>"/>

SOURCE Paul Capital Healthcare
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4
Related biology technology :

1. Vermillion Meets Minimum Bid Price and Receives NASDAQ Staff Determination Letter for Minimum Market Capitalization
2. Pharmasset Receives $10 Million of Working Capital
3. Alexza Completes $10 Million Equity Financing with Bio*One Capital to Initiate Commercial Manufacturing in Singapore
4. Insmed Announces Listing Transfer from Nasdaq Global Market to Nasdaq Capital Market
5. Bio-Clean International, Inc. to Present at Bluechip Capital Investment Forum
6. National Stem Cell Holding, Inc. Has Engaged BMA Securities to Assist and Advise the Company With Its Current Capital Raise of $3,500,000
7. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
8. AspenBio Pharma to Present at the Roth Capital Partners 20th Annual Growth Stock Conference
9. CryoLife to Present at Roth Capital Partners 20th Annual Orange County (OC) Growth Stock Conference
10. WaferGen to Present at the Roth Capital Partners 20th Annual OC Growth Stock Conference
11. Ardea Biosciences to Present at Roth Capital Partners 20th Annual OC Growth Stock Conference

Post Your Comments:

(Date:6/18/2013)... -- RegeneCure announced today the start ... Bone Regeneration (GBR) Dental Membrane as a bone stimulating aid ... encountered when patients have a tooth replaced with a dental ... the implant. Consequently there is often a need to support ... regenerates. The bone substitute material, in turn, needs to be ...

(Date:6/18/2013)... June 18, 2013 The "Bioinformatics Market By ... Knowledge Management Tools & Data Analysis Services) & Application (Genomics, ... the Major Market Drivers, Restraints, and Opportunities in ... Asia-Pacific and Rest of World. ... 22 Figures 364 ...

(Date:6/18/2013)... , June 18, 2013 ... ) has announced the addition of the ... [Liposomes, Microspheres, & Nanoparticles], Devices [Disposables & ... & Auto Injectors] & Therapeutics [Diabetes & ... report to their offering. ...

(Date:6/18/2013)... Inflamax Research Inc., a full ... Phase I-IV clinical trials, announced today that they ... Environmental Technologies (NAET), a specialty air conditioning & ... servicing of mobile Environmental Exposure Chambers (EECs) used ... , Inflamax Research has proprietary Next ...

Breaking Biology Technology:RegeneCure Starts Clinical Study Using Polymeric Bone Stimulating Membrane for Dental Implants 2 RegeneCure Starts Clinical Study Using Polymeric Bone Stimulating Membrane for Dental Implants 3 Bioinformatics Market Worth $7.5 Billion by 2017 2 Bioinformatics Market Worth $7.5 Billion by 2017 3 Injectable Drug Delivery Market by Formulations, Devices & Therapeutics - Global Forecasts to 2017 2 Injectable Drug Delivery Market by Formulations, Devices & Therapeutics - Global Forecasts to 2017 3 Inflamax Research Inc. Enters Strategic Partnership with Northern Air Environmental Technologies Inc. 2 Inflamax Research Inc. Enters Strategic Partnership with Northern Air Environmental Technologies Inc. 3

[0] RegeneCure Starts Clinical Study Using Polymeric Bone Stimulating Membrane for Dental Implants [0] Bioinformatics Market Worth $7.5 Billion by 2017 [0] Injectable Drug Delivery Market by Formulations, Devices & Therapeutics - Global Forecasts to 2017 [0] Inflamax Research Inc. Enters Strategic Partnership with Northern Air Environmental Technologies Inc.

... Eastern Time -, SAN FRANCISCO, Nov. 10 ... corporate progress and financial,results for the quarter ended September ... of significant,achievement and progress and was capped with the ... collaboration not only gives us,access to a world-class partner ...

... Conference Call Today To Discuss the Data and Ongoing ... Clinical Development Programs, ... announced today top-line data from its,SB-509-601 clinical trial, one of Sangamo,s ... SB-509 for diabetic,neuropathy (DN). The data demonstrate that repeat administration of ...

... Divestitures of Non-Core Product Lines -, HOPKINTON, ... CALP ) today reported third quarter financial,results ... line divestitures: the,sale of its AutoTrace(R) product line ... of its Pharmaceutical Development and Quality Analysis,(PDQ) product ...

Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601 Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs

(Date:6/18/2013)... DNA and this modification can occur in millions ... scientists believed that this epigenetic phenomenon actively reduced ... of researchers from the University of Geneva (UNIGE), ... the Faculty of Medicine, reveals that this is ... may play both a passive and active role ...

(Date:6/17/2013)... in patients with severe brain infections in Vietnam. Further ... responsible for the symptoms of disease. , The virus ... 644 patients with severe brain infections in the study, ... the 122 patients with non-infectious brain disorders that were ... system are often fatal and patients who do survive, ...

(Date:6/17/2013)... improving original foundations with more modern elements. Using this ... Kenneth P. Dietrich School of Arts and Sciences have ... delivery, gas storage, and gas transport more efficient and ... the latest issue of the Journal of the ... recent work builds upon Pitt Associate Professor of Chemistry ...

Breaking Biology News(10 mins):The secret of DNA methylation 2 New virus isolated from patients with severe brain infections 2 New virus isolated from patients with severe brain infections 3 'Chemical architects' build materials with potential applications in drug delivery and gas storage 2

[0] The secret of DNA methylation [0] New virus isolated from patients with severe brain infections [0] 'Chemical architects' build materials with potential applications in drug delivery and gas storage

... relatedness of an animal food protein to a human protein ... by scientists from the Institute of Food Research in Norwich ... proteins have the potential to become allergens, but the study ... to act as allergens depends on their evolutionary distance from ...

... pathway that plays a critical role in the growth ... important insight into the development of the vascular system ... inhibiting the blood vessels that fuel cancers, diabetic eye ... published online on Oct. 14 in Nature Genetics. was ...

... 2007Today at the Prostate Cancer Foundations Annual Scientific Retreat, ... foods such as tomatoes and fish, maintaining a healthy ... help prevent prostate cancer, and help men live healthier ... will be diagnosed with prostate cancer in their lifetime, ...

Cached Biology News:Animal food allergens unmasked 2 Study reveals a key to blood vessel growth and possible drug target 2 Study reveals a key to blood vessel growth and possible drug target 3 Leading researchers to reveal comprehensive dos and don'ts for prostate cancer 2 Leading researchers to reveal comprehensive dos and don'ts for prostate cancer 3

Animal food allergens unmasked Study reveals a key to blood vessel growth and possible drug target Leading researchers to reveal comprehensive dos and don'ts for prostate cancer

Blue Standard is 3-cyano-7-hydroxycoumarin....

Cyan Standard is 7-hydroxy-4-trifluoromethylcoumarin...

6-(2,4-dinitrophenyl)aminohexanoic acid, succinimidyl ester (DNP-X, SE)...

Endothelin-converting enzyme 1 (EC 3.4.24.71) (ECE-1). [Source:Uniprot/SWISSPROT;Acc:P42892] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....

Biology Products:

Fluorescent Standards Blue Standard from Invitrogen Fluorescent Standards Cyan Standard from Invitrogen 6-(2,4-dinitrophenyl)aminohexanoic acid, succinimidyl ester (DNP-X, SE) from Molecular Probes (Invitrogen)Rabbit Anti-Human ECE1 Polyclonal Antibody, Unconjugated from Atlas Antibodies